Cargando…
Management and outcome of topical beta-blockerinduced atrioventricular block
BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Clinics Cardive Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780015/ https://www.ncbi.nlm.nih.gov/pubmed/26659434 http://dx.doi.org/10.5830/CVJA-2015-030 |
_version_ | 1782419698117246976 |
---|---|
author | Özcan, Kazım Serhan Güngör, Barış Tekkeşin, Ahmet İlker Altay, Servet Ekmekçi, Ahmet Toprak, Ercan Yıldırım, Ersin Çalık, Nazmi Alper, Ahmet Taha Gürkan, Kadir Erdinler, İzzet Osmonov, Damirbek |
author_facet | Özcan, Kazım Serhan Güngör, Barış Tekkeşin, Ahmet İlker Altay, Servet Ekmekçi, Ahmet Toprak, Ercan Yıldırım, Ersin Çalık, Nazmi Alper, Ahmet Taha Gürkan, Kadir Erdinler, İzzet Osmonov, Damirbek |
author_sort | Özcan, Kazım Serhan |
collection | PubMed |
description | BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the Siyami Ersek Training and Research Hospital, between January 2009 and January 2013 with a diagnosis of AV block were included in the study. Subjects using ophthalmic beta-blockers were recruited and followed for permanent pacemaker requirement during hospitalisation and for three months after discontinuation of the drug. A permanent pacemaker was implanted in patients in whom AV block persisted beyond 72 hours or recurred during the follow-up period. RESULTS: A total of 1 122 patients were hospitalised with a diagnosis of AV block and a permanent pacemaker was implanted in 946 cases (84.3%) during the study period. Thirteen patients using ophthalmic beta-blockers for the treatment of glaucoma and no other rate-limiting drugs were included in the study. On electrocardiography, eight patients had complete AV block and five had high-degree AV block. The ophthalmic beta-blockers used were timolol in seven patients (55%), betaxolol in four (30%), and cartelol in two cases (15%). The mean duration of ophthalmic beta-blocker treatment was 30.1 ± 15.9 months. After drug discontinuation, in 10 patients the block persisted and a permanent pacemaker was implanted. During follow up, one more patient required pacemaker implantation. Therefore in total, pacemakers were implanted in 11 out of 13 patients (84.6%). The pacemaker implantation rate did not differ according to the type of topical beta-blocker used (p = 0.37). The presence of infra-nodal block on electrocardiography was associated with higher rates of pacemaker implantation. CONCLUSION: Our results indicate that topical beta-blockers for the treatment of glaucoma may cause severe conduction abnormalities and when AV block occurs, pacemaker implantation is required in a high percentage of the patients. |
format | Online Article Text |
id | pubmed-4780015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Clinics Cardive Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-47800152016-03-21 Management and outcome of topical beta-blockerinduced atrioventricular block Özcan, Kazım Serhan Güngör, Barış Tekkeşin, Ahmet İlker Altay, Servet Ekmekçi, Ahmet Toprak, Ercan Yıldırım, Ersin Çalık, Nazmi Alper, Ahmet Taha Gürkan, Kadir Erdinler, İzzet Osmonov, Damirbek Cardiovasc J Afr Cardiovascular Topics BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the Siyami Ersek Training and Research Hospital, between January 2009 and January 2013 with a diagnosis of AV block were included in the study. Subjects using ophthalmic beta-blockers were recruited and followed for permanent pacemaker requirement during hospitalisation and for three months after discontinuation of the drug. A permanent pacemaker was implanted in patients in whom AV block persisted beyond 72 hours or recurred during the follow-up period. RESULTS: A total of 1 122 patients were hospitalised with a diagnosis of AV block and a permanent pacemaker was implanted in 946 cases (84.3%) during the study period. Thirteen patients using ophthalmic beta-blockers for the treatment of glaucoma and no other rate-limiting drugs were included in the study. On electrocardiography, eight patients had complete AV block and five had high-degree AV block. The ophthalmic beta-blockers used were timolol in seven patients (55%), betaxolol in four (30%), and cartelol in two cases (15%). The mean duration of ophthalmic beta-blocker treatment was 30.1 ± 15.9 months. After drug discontinuation, in 10 patients the block persisted and a permanent pacemaker was implanted. During follow up, one more patient required pacemaker implantation. Therefore in total, pacemakers were implanted in 11 out of 13 patients (84.6%). The pacemaker implantation rate did not differ according to the type of topical beta-blocker used (p = 0.37). The presence of infra-nodal block on electrocardiography was associated with higher rates of pacemaker implantation. CONCLUSION: Our results indicate that topical beta-blockers for the treatment of glaucoma may cause severe conduction abnormalities and when AV block occurs, pacemaker implantation is required in a high percentage of the patients. Clinics Cardive Publishing 2015 /pmc/articles/PMC4780015/ /pubmed/26659434 http://dx.doi.org/10.5830/CVJA-2015-030 Text en Copyright © 2015 Clinics Cardive Publishing http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cardiovascular Topics Özcan, Kazım Serhan Güngör, Barış Tekkeşin, Ahmet İlker Altay, Servet Ekmekçi, Ahmet Toprak, Ercan Yıldırım, Ersin Çalık, Nazmi Alper, Ahmet Taha Gürkan, Kadir Erdinler, İzzet Osmonov, Damirbek Management and outcome of topical beta-blockerinduced atrioventricular block |
title | Management and outcome of topical beta-blockerinduced atrioventricular block |
title_full | Management and outcome of topical beta-blockerinduced atrioventricular block |
title_fullStr | Management and outcome of topical beta-blockerinduced atrioventricular block |
title_full_unstemmed | Management and outcome of topical beta-blockerinduced atrioventricular block |
title_short | Management and outcome of topical beta-blockerinduced atrioventricular block |
title_sort | management and outcome of topical beta-blockerinduced atrioventricular block |
topic | Cardiovascular Topics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780015/ https://www.ncbi.nlm.nih.gov/pubmed/26659434 http://dx.doi.org/10.5830/CVJA-2015-030 |
work_keys_str_mv | AT ozcankazımserhan managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT gungorbarıs managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT tekkesinahmetilker managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT altayservet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT ekmekciahmet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT toprakercan managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT yıldırımersin managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT calıknazmi managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT alperahmettaha managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT gurkankadir managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT erdinlerizzet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock AT osmonovdamirbek managementandoutcomeoftopicalbetablockerinducedatrioventricularblock |